M&A Deal Summary

Genoptix Acquires PersonalizeDx

On March 5, 2018, Genoptix acquired life science company PersonalizeDx from Rosetta Genomics for 1M USD

Acquisition Highlights
  • This is Genoptix’s 2nd transaction in the Life Science sector.
  • This is Genoptix’s 2nd largest (disclosed) transaction.
  • This is Genoptix’s 2nd transaction in the United States.
  • This is Genoptix’s 1st transaction in California.

M&A Deal Summary
Date 2018-03-05
Target PersonalizeDx
Sector Life Science
Buyer(s) Genoptix
Sellers(s) Rosetta Genomics
Deal Type Divestiture
Deal Value 1M USD

Target

PersonalizeDx

Lake Forest, California, United States
PersonalizeDx Labs provides as a service molecular tests in pharmacogenomics, genetic disorders, oncology and infectious disease which will serve as a valuable aid for clinicians in diagnosing patients early and enable appropriate therapeutic intervention to enhance patient care.

Search 200,500 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Genoptix

Carlsbad, California, United States
Category Company
Founded 1999
Sector Healthcare Services
Employees508
DESCRIPTION

Genoptix, Inc. is one of the largest hematopathology testing laboratories in the U.S., providing thousands of oncologists and pathologists across the United States with comprehensive testing solutions in hematology and solid tumor molecular profiling. Genoptix, Inc. was founded in 1999 and is based in Carlsbad, California.

DEAL STATS #
Overall 3 of 3
Sector (Life Science) 2 of 2
Type (Divestiture) 1 of 1
State (California) 1 of 1
Country (United States) 2 of 2
Year (2018) 1 of 1
Size (of disclosed) 2 of 2
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2017-12-15 Rosetta Genomics

Rehovot, Israel

Rosetta Genomics Ltd. is a developer and provider of microRNA-based and other molecular diagnostics. Rosetta’s integrative research platform combining bioinformatics and state-of-the-art laboratory processes has led to the discovery of hundreds of biologically validated novel human microRNAs.

Buy $10M

Seller(S) 1

SELLER

Rosetta Genomics

Rehovot, Israel
Category Company
Founded 2000
Sector Life Science
Employees52
Revenue 1M USD (2014)
DESCRIPTION

Rosetta Genomics Ltd. is a developer and provider of microRNA-based and other molecular diagnostics. Rosetta’s integrative research platform combining bioinformatics and state-of-the-art laboratory processes has led to the discovery of hundreds of biologically validated novel human microRNAs.

DEAL STATS #
Overall 1 of 1
Sector (Life Science) 1 of 1
Type (Divestiture) 1 of 1
State (California) 1 of 1
Country (United States) 1 of 1
Year (2018) 1 of 1
Size (of disclosed) 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2015-04-09 PersonalizeDx

Lake Forest, California, United States

PersonalizeDx Labs provides as a service molecular tests in pharmacogenomics, genetic disorders, oncology and infectious disease which will serve as a valuable aid for clinicians in diagnosing patients early and enable appropriate therapeutic intervention to enhance patient care.

Buy $2M
Mergr

Product

Company

Legal